BACKGROUND: Alterations of serotonin neurotransmission are implicated in both mood disorders and schizophrenia. Specific serotonin-receptor-based abnormalities in these psychiatric illnesses have been intensively studied; however, it has been difficult to draw any conclusions because of a lack of consensus. These inconsistencies have most likely arisen from the unavailability of selective ligands. METHODS: Our study used in situ hybridization to quantify 5-HT(1A), 5-HT(1B), and 5-HT(2A) mRNA levels in the hippocampus (HC) and 5-HT(1A) and 5-HT(2A) mRNA levels in the dorsolateral prefrontal cortex (DLPFC) of subjects with a history of major depression disorder (MDD), bipolar disorder (BPD), schizophrenia, and a normal comparison group (15 subjects per group). RESULTS: In the DLPFC, there is a significant decrease in 5-HT(1A) mRNA of subjects with MDD and in 5-HT(2A) mRNA of subjects with BPD. Subjects with MDD have a significant decrease in 5-HT(1A) mRNA in the HC; subjects with BPD and schizophrenia had increased 5-HT(1B) mRNA levels and a significant decrease in 5-HT(2A) mRNA levels in the hippocampal formation. CONCLUSIONS: Alterations in 5-HT(1A,) 5-HT(1B), and 5-HT(2A) mRNA levels in the brains of subjects with both mood disorders and schizophrenia add further support for hypothesis of dysregulation of the serotonergic system in these psychiatric disorders.
BACKGROUND: Alterations of serotonin neurotransmission are implicated in both mood disorders and schizophrenia. Specific serotonin-receptor-based abnormalities in these psychiatric illnesses have been intensively studied; however, it has been difficult to draw any conclusions because of a lack of consensus. These inconsistencies have most likely arisen from the unavailability of selective ligands. METHODS: Our study used in situ hybridization to quantify 5-HT(1A), 5-HT(1B), and 5-HT(2A) mRNA levels in the hippocampus (HC) and 5-HT(1A) and 5-HT(2A) mRNA levels in the dorsolateral prefrontal cortex (DLPFC) of subjects with a history of major depression disorder (MDD), bipolar disorder (BPD), schizophrenia, and a normal comparison group (15 subjects per group). RESULTS: In the DLPFC, there is a significant decrease in 5-HT(1A) mRNA of subjects with MDD and in 5-HT(2A) mRNA of subjects with BPD. Subjects with MDD have a significant decrease in 5-HT(1A) mRNA in the HC; subjects with BPD and schizophrenia had increased 5-HT(1B) mRNA levels and a significant decrease in 5-HT(2A) mRNA levels in the hippocampal formation. CONCLUSIONS: Alterations in 5-HT(1A,) 5-HT(1B), and 5-HT(2A) mRNA levels in the brains of subjects with both mood disorders and schizophrenia add further support for hypothesis of dysregulation of the serotonergic system in these psychiatric disorders.
Authors: G M Alexander; J D Graef; J A Hammarback; B K Nordskog; E J Burnett; J B Daunais; A J Bennett; D P Friedman; S J Suomi; D W Godwin Journal: Neuroscience Date: 2012-01-21 Impact factor: 3.590
Authors: Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg Journal: Neurosci Biobehav Rev Date: 2012-07-07 Impact factor: 8.989
Authors: Alexis C Edwards; Fazil Aliev; Laura J Bierut; Kathleen K Bucholz; Howard Edenberg; Victor Hesselbrock; John Kramer; Samuel Kuperman; John I Nurnberger; Marc A Schuckit; Bernice Porjesz; Danielle M Dick Journal: Psychiatr Genet Date: 2012-02 Impact factor: 2.458
Authors: O Nakagawasai; A Murata; Y Arai; A Ohba; K Wakui; S Mitazaki; F Niijima; K Tan-No; T Tadano Journal: J Neural Transm (Vienna) Date: 2007-03-20 Impact factor: 3.575
Authors: René Bernard; Ilan A Kerman; Fan Meng; Simon J Evans; Irmgard Amrein; Edward G Jones; William E Bunney; Huda Akil; Stanley J Watson; Robert C Thompson Journal: J Neurosci Methods Date: 2008-11-25 Impact factor: 2.390
Authors: S J Evans; P V Choudary; C R Neal; J Z Li; M P Vawter; H Tomita; J F Lopez; R C Thompson; F Meng; J D Stead; D M Walsh; R M Myers; W E Bunney; S J Watson; E G Jones; H Akil Journal: Proc Natl Acad Sci U S A Date: 2004-10-13 Impact factor: 11.205
Authors: Bernadeta Szewczyk; Paul R Albert; Ariel M Burns; Margaret Czesak; James C Overholser; George J Jurjus; Herbert Y Meltzer; Lisa C Konick; Lesa Dieter; Nicole Herbst; Warren May; Grazyna Rajkowska; Craig A Stockmeier; Mark C Austin Journal: Int J Neuropsychopharmacol Date: 2008-06-19 Impact factor: 5.176